Clinical Efficacy of Stereotactic Radiotherapy and Microwave Ablation for Liver Metastases From Colorectal Cancer.

Summary

Data of 100 colorectal cancer patients with liver metastases who received stereotactic radiotherapy of Cyberknife or microwave ablation in the multicenter of the research group from June 2019 to May 2021 were collected, as well as follow-up data.To evaluate the clinical efficacy of stereotactic radiotherapy and microwave ablation in liver metastases.In addition, the local control rate and side effects of stereotactic radiotherapy and microwave ablation in the treatment of liver metastases were explored, and the efficacy and safety of different doses of stereotactic radiotherapy were determined.

Conditions

• Radiotherapy
• Microwave Ablation
• Liver Metastases
• Colorectal Cancer

Interventions

RADIATION

stereotactic radiotherapy

The liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).

OTHER

microwave alabation

The colorectal cancer patients with liver metastases will receive microwave ablation.3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.

Sponsors & Collaborators

• Beijing 302 Hospital

  collaborator OTHER

• Tengzhou Central People's Hospital

  collaborator OTHER_GOV

• Guangxi Ruikang Hospital

  collaborator OTHER

• Hunan Aerospace Hospital

  collaborator UNKNOWN

• Beijing Ditan Hospital

  collaborator OTHER

• Peking University Third Hospital

  lead OTHER

Principal Investigators

• Junjie U Wang, MD · Peking University Third Hospital

• Fei U Xu, M Med · Peking University Third Hospital

• Xuezhang Duan, MD · Beijing 302 Hospital

• Kaixian Zhang, MD · Tengzhou Central People's Hospital

• Wei Li, MD · Beijing Ditan Hospital

• Hui Xie, MD · Beijing 302 Hospital

• Zuping Lian, MD · Guangxi Ruikang Hospital

• Xian Xu, M Med · Hunan Aerospace Hospital

• Fuxin Guo, MD · Peking University Third Hospital

• Jing Sun, M Med · Beijing 302 Hospital

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-06-03

Primary Completion

2021-05-31

Completion

2022-05-31

Countries

• China

Study Locations